Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications

Fran Šaler, Ivan Paladin, Ivana Blažeković, Ema Boras, Ružica Tokalić, Marin Viđak, Livia Puljak

Open source

DOI
10.1016/j.jclinepi.2026.112227
Published
2026-06
Container
Journal of Clinical Epidemiology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jclinepi.2026.112227,
  title = {Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications},
  author = {Fran Šaler and Ivan Paladin and Ivana Blažeković and Ema Boras and Ružica Tokalić and Marin Viđak and Livia Puljak},
  year = {2026},
  journal = {Journal of Clinical Epidemiology},
  doi = {10.1016/j.jclinepi.2026.112227},
  url = {https://doi.org/10.1016/j.jclinepi.2026.112227}
}

RIS

TY  - JOUR
TI  - Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications
AU  - Fran Šaler
AU  - Ivan Paladin
AU  - Ivana Blažeković
AU  - Ema Boras
AU  - Ružica Tokalić
AU  - Marin Viđak
AU  - Livia Puljak
PY  - 2026
JO  - Journal of Clinical Epidemiology
DO  - 10.1016/j.jclinepi.2026.112227
UR  - https://doi.org/10.1016/j.jclinepi.2026.112227
ER  - 

APA

Šaler, F., Paladin, I., Blažeković, I., Boras, E., Tokalić, R., Viđak, M., & Puljak, L. (2026). Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications. Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2026.112227

Source records